{"filing":{"accession_number":"0001193125-26-315163","cik":"0001936258","ticker":"NAMSW","company_name":"NewAmsterdam Pharma Co N.V.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-24","primary_document":"nams-20260724.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526315163/nams-20260724.htm"},"events":[{"id":20324,"run_id":18299,"accession_number":"0001193125-26-315163","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NewAmsterdam Pharma announced receipt of a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European Medicines Agency recommending marketing authorization for Ubeslo® and Evlarco® (obicetrapib-based therapies). This is a significant regulatory milestone in the clinical development and commercialization pathway for the company's lead product candidate. While not yet final approval (the European Commission decision is expected in 2H26), the positive CHMP opinion represents material progress toward a key operational and commercial objective for a late-stage biopharmaceutical company, affecting investor assessment of the company's prospects and value.","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19653,"accession_number":"0001193125-26-315163","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NewAmsterdam Pharma announced receipt of a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European Medicines Agency recommending marketing authorization for Ubeslo® and Evlarco® (obicetrapib-based therapies). This is a significant regulatory milestone in the clinical development and commercialization pathway for the company's lead product candidate. While not yet final approval (the European Commission decision is expected in 2H26), the positive CHMP opinion represents material progress toward a key operational and commercial objective for a late-stage biopharmaceutical company, affecting investor assessment of the company's prospects and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T12:04:42.201003+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19653,"accession_number":"0001193125-26-315163","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NewAmsterdam Pharma announced receipt of a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European Medicines Agency recommending marketing authorization for Ubeslo® and Evlarco® (obicetrapib-based therapies). This is a significant regulatory milestone in the clinical development and commercialization pathway for the company's lead product candidate. While not yet final approval (the European Commission decision is expected in 2H26), the positive CHMP opinion represents material progress toward a key operational and commercial objective for a late-stage biopharmaceutical company, affecting investor assessment of the company's prospects and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T12:04:42.201003+00:00","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-07-24"}]}